SyntheticMR announced that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This milestone marks a significant advancement in quantitative MRI technology, offering unprecedented resolution and accuracy in brain imaging. SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function.

Furthermore, the resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions. With this clearance, SyntheticMR reaffirms its commitment to advancing medical imaging technology and providing clinicians with innovative tools to enhance patient care. SyMRI 3D opens up new possibilities for precise diagnosis, treatment planning, and monitoring, ultimately improving patient outcomes.